• Je něco špatně v tomto záznamu ?

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis

S. Vermeire, M. Lukáš, F. Magro, S. Adsul, D. Lindner, M. Rosario, J. Roth, S. Danese

. 2020 ; 14 (8) : 1066-1073. [pub] 2020Sep07

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, klinické zkoušky, fáze IV, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026566

BACKGROUND AND AIMS: Vedolizumab was shown to be safe and effective for the treatment of Crohn's disease [CD] and ulcerative colitis [UC] in the GEMINI Long-Term Safety [LTS] study. The vedolizumab Extended Access Program [XAP] provides patients with continued treatment. This XAP pharmacokinetics [PK] sub-study investigated vedolizumab efficacy, safety, and PK. METHODS: Vedolizumab dosing frequency was reduced from every 4 weeks [Q4W] to every 8 weeks [Q8W] at XAP enrolment, and patients were followed for 56 weeks. Outcomes included: efficacy, loss of clinical benefit, and re-escalation to Q4W dosing; and vedolizumab PK, immunogenicity, and adverse events. RESULTS: Among 167 enrolled patients [CD = 88, UC = 79], 80 [91%] with CD and 73 [92%] with UC completed 56 weeks; 76 [86%] and 71 [90%] with CD and UC, respectively, remained on Q8W dosing for 56 weeks. Clinical remission, corticosteroid-free clinical remission, and C-reactive protein levels were stable among patients remaining on Q8W through Week 56. Four patients with CD and two with UC resumed Q4W dosing [three with CD regained clinical response]. Patients with CD who completed Week 56 on Q8W dosing had median trough vedolizumab concentrations of 43.6 µg/mL at enrolment and 10.4 µg/mL at Week 56; concentrations were 42.4 µg/mL and 13.3 µg/mL, respectively, in patients with UC. Treatment-related adverse events were infrequent; no new or serious adverse events related to vedolizumab were reported. CONCLUSIONS: In the XAP-PK sub-study, adherence to Q8W dosing was high, with no loss of efficacy; very few patients required re-escalation to Q4W. There were no new safety signals.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026566
003      
CZ-PrNML
005      
20211026132812.0
007      
ta
008      
211013s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ecco-jcc/jjaa027 $2 doi
035    __
$a (PubMed)32060515
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Vermeire, Séverine $u Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium
245    10
$a Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis / $c S. Vermeire, M. Lukáš, F. Magro, S. Adsul, D. Lindner, M. Rosario, J. Roth, S. Danese
520    9_
$a BACKGROUND AND AIMS: Vedolizumab was shown to be safe and effective for the treatment of Crohn's disease [CD] and ulcerative colitis [UC] in the GEMINI Long-Term Safety [LTS] study. The vedolizumab Extended Access Program [XAP] provides patients with continued treatment. This XAP pharmacokinetics [PK] sub-study investigated vedolizumab efficacy, safety, and PK. METHODS: Vedolizumab dosing frequency was reduced from every 4 weeks [Q4W] to every 8 weeks [Q8W] at XAP enrolment, and patients were followed for 56 weeks. Outcomes included: efficacy, loss of clinical benefit, and re-escalation to Q4W dosing; and vedolizumab PK, immunogenicity, and adverse events. RESULTS: Among 167 enrolled patients [CD = 88, UC = 79], 80 [91%] with CD and 73 [92%] with UC completed 56 weeks; 76 [86%] and 71 [90%] with CD and UC, respectively, remained on Q8W dosing for 56 weeks. Clinical remission, corticosteroid-free clinical remission, and C-reactive protein levels were stable among patients remaining on Q8W through Week 56. Four patients with CD and two with UC resumed Q4W dosing [three with CD regained clinical response]. Patients with CD who completed Week 56 on Q8W dosing had median trough vedolizumab concentrations of 43.6 µg/mL at enrolment and 10.4 µg/mL at Week 56; concentrations were 42.4 µg/mL and 13.3 µg/mL, respectively, in patients with UC. Treatment-related adverse events were infrequent; no new or serious adverse events related to vedolizumab were reported. CONCLUSIONS: In the XAP-PK sub-study, adherence to Q8W dosing was high, with no loss of efficacy; very few patients required re-escalation to Q4W. There were no new safety signals.
650    _2
$a dospělí $7 D000328
650    12
$a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D061067
650    12
$a ulcerózní kolitida $x diagnóza $x farmakoterapie $x imunologie $7 D003093
650    12
$a Crohnova nemoc $x diagnóza $x farmakoterapie $x imunologie $7 D003424
650    _2
$a imunologická odpověď na dávku $7 D004306
650    _2
$a monitorování léčiv $x metody $7 D016903
650    _2
$a vysazování léků $x metody $7 D000084862
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gastrointestinální látky $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D005765
650    _2
$a lidé $7 D006801
650    _2
$a intravenózní infuze $7 D007262
650    _2
$a integriny $x antagonisté a inhibitory $7 D016023
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a výsledky a postupy - zhodnocení (zdravotní péče) $7 D010043
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a klinické zkoušky, fáze IV $7 D017429
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Lukáš, Milan $u IBD Clinical and Research Centre, ISCARE Clinical Centre, Prague, Czech Republic
700    1_
$a Magro, Fernando $u Department of Gastroenterology, Centro Hospitalar São João, Porto, Portugal
700    1_
$a Adsul, Shashi $u Takeda Pharmaceuticals International AG, Zurich, Switzerland
700    1_
$a Lindner, Dirk $u Takeda Pharmaceuticals International AG, Zurich, Switzerland
700    1_
$a Rosario, Maria $u Takeda Development Center Americas Inc., Cambridge, MA, USA
700    1_
$a Roth, Jeannine $u Takeda Pharmaceuticals International AG, Zurich, Switzerland
700    1_
$a Danese, Silvio $u Department of Gastroenterology, IBD Center, Humanitas Research Hospital, Rozzano, Italy
773    0_
$w MED00166945 $t Journal of Crohn's & colitis $x 1876-4479 $g Roč. 14, č. 8 (2020), s. 1066-1073
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32060515 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132818 $b ABA008
999    __
$a ok $b bmc $g 1715330 $s 1147073
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 14 $c 8 $d 1066-1073 $e 2020Sep07 $i 1876-4479 $m Journal of Crohn's and colitis $n J Crohns Colitis $x MED00166945
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace